Speiser, D. E. & Bachmann, M. F. COVID-19: Mechanisms of Vaccination and Immunity. Vaccines (Basel) 8, 404 (2020).
Dobler, N. A. & Carbon, C. C. Vaccination in opposition to SARS-CoV-2: a human enhancement story. Transl. Med. Commun. 6, 27 (2021).
Mallapaty, S. China’s COVID vaccines have been essential – now immunity is waning. Nature 598, 398–399 (2021).
McMenamin, M. E. & Cowling, B. J. CoronaVac efficacy information from Turkey. Lancet 398, 1873–1874 (2021).
Davis, C. et al. Decreased neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. PLoS Pathog. 17, e1010022 (2021).
Nadesalingam, A. et al. Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient sufferers and health-care employees within the UK. Lancet Microbe 2, e416–e418 (2021).
Choi, A. et al. Security and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in wholesome adults: an interim evaluation. Nat. Med. 27, 2025–2031 (2021).
Stuart, A. S. V. et al. Immunogenicity, security, and reactogenicity of heterologous COVID-19 major vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines within the UK (Com-COV2): a single-blind, randomised, part 2, non-inferiority trial. Lancet 399, 36–49 (2021).
Barros-Martins, J. et al. Immune responses in opposition to SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat. Med. 27, 1525–1529 (2021).
He, X., He, C., Hong, W., Zhang, Okay. & Wei, X. The challenges of COVID-19 Delta variant: prevention and vaccine growth. MedComm 2, 846–854 (2021).
Lopez Bernal, J. et al. Effectiveness of Covid-19 Vaccines in opposition to the B.1.617.2 (Delta) Variant. N. Engl. J. Med. 385, 585–594 (2021).
Dubey, A., Choudhary, S., Kumar, P. & Tomar, S. Rising SARS-CoV-2 Variants: Genetic Variability and Medical Implications. Curr. Microbiol. 79, 20 (2021).
Viana, R. et al. Fast epidemic enlargement of the SARS-CoV-2 Omicron variant in southern Africa. Nature 603, 679–686 (2022).
Ledford, H. How extreme are Omicron infections? Nature 600, 577–578 (2021).
Callaway, E. & Ledford, H. How unhealthy is Omicron? What scientists know thus far. Nature 600, 197–199 (2021).
Maslo, C. et al. Traits and Outcomes of Hospitalized Sufferers in South Africa Through the COVID-19 Omicron Wave In contrast With Earlier Waves. JAMA 327, 583–584 (2021).
Kozlov, M. Waning COVID super-immunity raises questions on Omicron. Nature, https://doi.org/10.1038/d41586-021-03674-1 (2021).
Andrews, N. et al. Covid-19 Vaccine Effectiveness in opposition to the Omicron (B.1.1.529) Variant. N. Engl J. Med. 386, 1532–1546 (2022).
Carreño, J. M. et al. Exercise of convalescent and vaccine serum in opposition to a B.1.1.529 variant SARS-CoV-2 isolate. Nature 602, 682–688 (2022).
Garcia-Beltran, W. F., et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity in opposition to SARS-CoV-2 Omicron variant. Cell 185, 457–466 (20212).
Gruell, H. et al. mRNA booster immunization elicits potent neutralizing serum exercise in opposition to the SARS-CoV-2 Omicron variant. Nat. Med. 28, 477–480 (2022).
Marcotte, H. et al. Immunity to SARS-CoV-2 as much as 15 months after an infection. iScience 25, 103743 (2021).
Sherina, N. et al. Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 sufferers 6-8 months after the an infection. Med (N.Y) 2, 281–295 e284 (2021).
Fakhroo, A., AlKhatib, H. A., Al Thani, A. A. & Yassine, H. M. Reinfections in COVID-19 Sufferers: Influence of Virus Genetic Variability and Host Immunity. Vaccines (Basel) 9, 1168 (2021).
Knezevic, I. et al. WHO Worldwide Normal for analysis of the antibody response to COVID-19 vaccines: name for pressing motion by the scientific group. Lancet Microbe 3, e235–e240 (2021).
Haveri, A., et al. Neutralizing antibodies to SARS-CoV-2 Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in well being care employees and aged topics. Eur. J. Immunol. https://doi.org/10.1002/eji.202149785 (2022).
Sheward, D. J., et al. Variable lack of antibody efficiency in opposition to SARS-CoV-2 B. 1.1. 529 (Omicron). bioRxiv, https://doi.org/10.1101/2021.12.19.473354 (2021).
Roessler, A., Riepler, L., Bante, D., von Laer, D. & Kimpel, J. J. M. SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Individuals. N. Engl. J. Med. 386, 698–700 (2022).
Planas, D. et al. Appreciable escape of SARS-CoV-2 variant Omicron to antibody neutralization. Nature 602, 671–675 (2022).
Cele, S. et al. SARS-CoV-2 Omicron has in depth however incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for an infection. Nature 602, 654–656 (2022).
Hastie, Okay. M. et al. Defining variant-resistant epitopes focused by SARS-CoV-2 antibodies: a worldwide consortium examine. Science 374, 472–478 (2021).
Khoury, D. S. et al. Neutralizing antibody ranges are extremely predictive of immune safety from symptomatic SARS-CoV-2 an infection. Nat. Med 27, 1205–1211 (2021).
Pagliari, M., et al. Omicron Neutralizing and Anti-SARS-CoV-2 S-RBD Antibodies in Naïve and Convalescent Populations After Homologous and Heterologous Boosting With an mRNA Vaccine. Lancet https://doi.org/10.2139/ssrn.4016530 (2022).
Mok, C. Okay. P. et al. Comparability of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong. Respirology 27, 301–310 (2022).
Liu, Z. et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe 29, 477–488 e474 (2021).
Wang, Okay., et al. A 3rd dose of inactivated vaccine augments the efficiency, breadth, and period of anamnestic responses in opposition to SARS-CoV-2. medRxiv https://doi.org/10.1101/2021.09.02.21261735 (2021).
Wesemann, D. R. Omicron’s message on vaccines: boosting begets breadth. Cell 185, 411–413 (2022).
Bartsch, Y. et al. Omicron variant Spike-specific antibody binding and Fc exercise is preserved in recipients of mRNA or inactivated COVID-19 vaccines. Sci. Transl. Med. 14, eabn9243 (2022).
Tarke, A. et al. SARS-CoV-2 vaccination induces immunological reminiscence capable of cross-recognize variants from Alpha to Omicron. Cell 185, 847–859 (2022).
Keeton, R. et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature 603, 488–492 (2022).
Gagne, M. et al. mRNA-1273 or mRNA-Omicron increase in vaccinated macaques elicits comparable B cell enlargement, neutralizing responses, and safety from Omicron. Cell 185, 1556–1571 (2022).
Gao, Y. et al. Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. Nat. Med. 28, 472–476 (2022).
GeurtsvanKessel, C. H. et al. Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients. Sci. Immunol. 7, eabo2202 (2022).
Callaway, E. Why does the Omicron sub-variant unfold quicker than the unique? Nature 602, 556–557 (2022).
Chen, J. & Wei, G. W. Omicron BA.2 (B.1.1.529.2): excessive potential for changing into the subsequent dominating variant. J Phys. Chem. Lett. 13, 3840–3849 (2022).
Yu, J. et al. Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. N. Engl. J. Med. 386, 1579–1580 (2022).
Perez-Then, E. et al. Neutralizing antibodies in opposition to the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Nat. Med. 28, 481–485 (2022).
Cheng, S. M. S. et al. Neutralizing antibodies in opposition to the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat. Med. 28, 486–489 (2022).
Costa Clemens, S. A. et al. Heterologous versus homologous COVID-19 booster vaccination in earlier recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a part 4, non-inferiority, single blind, randomised examine. Lancet 399, 521–529 (2022).
Schubert, M. et al. Human serum from SARS-CoV-2 vaccinated and COVID-19 sufferers exhibits decreased binding to the RBD of SARS-CoV-2 Omicron variant compared to the unique Wuhan pressure and the Beta and Delta variants. BMC Med. 3, 20,102 (2021).
Bertoglio, F. et al. A SARS-CoV-2 neutralizing antibody chosen from COVID-19 sufferers binds to the ACE2-RBD interface and is tolerant to most recognized RBD mutations. Cell Rep. 36, 109433 (2021).
Korn, J. et al. Baculovirus-free insect cell expression system for prime yield antibody and antigen manufacturing. Sci. Rep. 10, 21393 (2020).
Bonelli, F. et al. Medical and Analytical Efficiency of an Automated Serological Check That Identifies S1/S2-Neutralizing IgG in COVID-19 Sufferers Semiquantitatively. J. Clin. Microbiol. 58, e01224–01220 (2020).
Percivalle, E. et al. Prevalence of SARS-CoV-2 particular neutralising antibodies in blood donors from the Lodi Purple Zone in Lombardy, Italy, as at 06 April 2020. Eur. Surveill. 25, 2001031 (2020).